Comprehensive Stock Comparison
Compare Immunovant, Inc. (IMVT) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | CANF | Beta 0.36 vs IMVT's 1.08 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs IMVT's +34.6% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs CANF's -114.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for autoimmune diseases. It generates no current revenue but aims to monetize through future drug sales if its lead candidate batoclimab — currently in Phase II trials for multiple autoimmune conditions — gains regulatory approval. The company's key advantage lies in its novel FcRn inhibitor technology platform, which could offer improved safety and efficacy profiles compared to existing autoimmune treatments.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CANF leads in 3 of 6 categories (Financial Metrics, Total Returns). IMVT leads in 2 (Valuation Metrics, Profitability & Efficiency).
Financial Metrics (TTM)
CANF and IMVT operate at a comparable scale, with $560,000 and $0 in trailing revenue.
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $560,000 |
| EBITDAEarnings before interest/tax | -$487M | -$9M |
| Net IncomeAfter-tax profit | -$464M | -$9M |
| Free Cash FlowCash after capex | -$423M | -$8M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -16.0% |
| Net MarginNet income ÷ Revenue | — | -15.7% |
| FCF MarginFCF ÷ Revenue | — | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +36.4% |
Valuation Metrics
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $5.6B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | -10.16x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9999.00x |
| Price / BookPrice ÷ Book value/share | 5.94x | 6.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-2 for CANF. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CANF's 0.02x. On the Piotroski fundamental quality scale (0–9), IMVT scores 2/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | -47.1% | -2.1% |
| ROA (TTM)Return on assets | -44.1% | -114.0% |
| ROICReturn on invested capital | — | -4.5% |
| ROCEReturn on capital employed | -66.1% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.00x | 0.02x |
| Net DebtTotal debt minus cash | -$714M | -$5M |
| Cash & Equiv.Liquid assets | $714M | $5M |
| Total DebtShort + long-term debt | $98,000 | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in IMVT five years ago would be worth $18,673 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs IMVT's +34.6%. The 3-year compound annual growth rate (CAGR) favors CANF at 20.6% vs IMVT's 16.7% — a key indicator of consistent wealth creation.
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | +7.0% | +2059.1% |
| 1-Year ReturnPast 12 months | +34.6% | +169.9% |
| 3-Year ReturnCumulative with dividends | +58.7% | +75.3% |
| 5-Year ReturnCumulative with dividends | +86.7% | -76.5% |
| 10-Year ReturnCumulative with dividends | +178.7% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +16.7% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than IMVT's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.36x |
| 52-Week HighHighest price in past year | $29.25 | $4.93 |
| 52-Week LowLowest price in past year | $12.72 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +94.8% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 58.1 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 4.3M |
Analyst Outlook
Wall Street rates IMVT as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 28.6% for IMVT (target: $36).
| Metric | IMVTImmunovant, Inc. | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $35.67 | $7.25 |
| # AnalystsCovering analysts | 23 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 100 | 165.8 | +65.8% |
| Can-Fite BioPharma … (CANF) | 100 | 33.04 | -67.0% |
Immunovant, Inc. (IMVT) returned +87% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%. A $10,000 investment in IMVT 5 years ago would be worth $18,673 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | $0.00 | $0.00 | — |
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | -13.67 | -2.73 | +80.0% |
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
Chart 4Free Cash Flow — 5 Years
Immunovant, Inc. generated $-377M FCF in 2025 (-351% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
IMVT vs CANF: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is IMVT or CANF a better buy right now?
Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMVT or CANF?
Over the past 5 years, Immunovant, Inc. (IMVT) delivered a total return of +86.7%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in IMVT five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: IMVT returned +178.7% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMVT or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Immunovant, Inc.'s 1.08β — meaning IMVT is approximately 199% more volatile than CANF relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for Can-Fite BioPharma Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — IMVT or CANF?
Immunovant, Inc. (IMVT) is the more profitable company, earning 0.0% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0.0% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IMVT or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IMVT or CANF better for a retirement portfolio?
For long-horizon retirement investors, Can-Fite BioPharma Ltd. (CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36)). Both have compounded well over 10 years (CANF: -98.5%, IMVT: +178.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IMVT and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.